Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: The multicenter, single-arm, phase II trial (Simon's two stage design) evaluated the efficacy of mFOLFOX6 + cetuximab (500 mg/m2) q2w as 1st line therapy in KRAS wt mCRC. Final extended molecular and subgroup analyses are presented. Methods: Primary endpoint was response rate (ORR) per RECIST 1.0. In stage 1 and 2, 13 and 25 responders were needed in 37 and 53 pts, respectively, to further evaluate this therapy (H p > 0.55).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
